Preparation and in vitro evaluation of salbutamol-loaded lipid microparticles for sustained release pulmonary therapy

Journal of Microencapsulation

Volumn 29, Issue 3, 2012, Pages 225-233

  Scalia, Santo ^a   Salama, Rania ^b,c   Young, Paul ^b   Traini, Daniela ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Aerodynamic diameter; Dry powder inhaler; Inhalation; Polar drug encapsulation

Indexed keywords

DRUG CARRIER; GLYCEROL BEHENATE; LIPID MICROPARTICLE; PHOSPHATIDYLCHOLINE; SALBUTAMOL; STEARIC ACID; TRISTEARIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EMULSION; IN VITRO STUDY; LASER DIFFRACTION; MICROPARTICLE ENZYME IMMUNOASSAY; PARTICLE SIZE; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; ULTRASOUND;

AEROSOLS; ALBUTEROL; BRONCHODILATOR AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DESIGN; FATTY ACIDS; HUMANS; LIPIDS; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; PHOSPHATIDYLCHOLINES; POWDERS; PULMONARY MEDICINE; STEARIC ACIDS; TRIGLYCERIDES; X-RAY DIFFRACTION;

EID: 84859598005     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2011.646326     Document Type: Article

References (46)

1. Adi S, Adi H, Tang P, Traini D, Chan HK, Young P. Micro-particle corrugation, adhesion and inhalation efficiency. Eur J Pharm Sci, 2008;35:12-18.
2. Alhusban F, Seville PC. Carbomer - Modified spray-dried respirable powders for pulmonary delivery of salbutamol sulphate. J Microencapsul, 2009;26:444-55.
3. Armstrong DJ, Elliott PNC, Ford JL, Gadson D, McCarthy GP, Rostron C, Worsley MD. Poly(DL-lactic acid) microspheres incorporating histological dyes for intra-pulmonary histopathological investigations. J Pharm Pharmacol, 1996;48:258-62.
4. Berlinski A, Willis JR, Leisenring T. In-vitro comparison of 4 large-volume nebulisers in 8 hours of continuous nebulization. Respir Care, 2010;55:1671-9.
5. Bodmeier R, Wang J, Bhagwatwar H. Process and formulation variables in the preparation of wax microparticles by a melt dispersion technique. II. W/O/W multiple emulsion technique for water-soluble drugs. J Microencapsul, 1992;9:99-107.
6. Bousquillon C, Lombry C, Preat V, Vanbever R. Comparison of particle sizing techniques in the case of inhalation dry powders. J Pharm Sci, 2001;90:2032-41. (Pubitemid 33144449)
7. Chmelik F, Doughty A. Objective measurements of compliance in asthma treatment. Ann Allergy, 1994;73:527-32.
8. Cook RO, Pannu RK, Kellaway IW. Novel sustained release microspheres for pulmonary drug delivery. J Control Release, 2005;5:79-90. (Pubitemid 40615237)
9. Corrigan DO, Healy AM, Corrigan OI. Preparation and release of salbutamol from chitosan and chitosan co-spray dried compacts and multiparticulates. Eur J Pharm Biopharm, 2006;62:295-305. (Pubitemid 43356579)
10. Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: Recent developments and prospects. Crit Rev Ther Drug Carrier Syst, 2002;19:425-98. (Pubitemid 36314479)
11. D'Alonzo GE, Crocetti JG, Smolensky MH. Circadian rhythms in pharmacokinetics and clinical effects of -agonist, theophylline and anticholinergic medications in the treatment of nocturnal asthma. Chronobiol Int, 1999;16:663-82. (Pubitemid 29463834)
12. Dalpiaz A, Mezzena M, Scaturin A, Scalia S. Solid lipid microparticles for the stability enhancement of the polar drug N6-cyclopentyladenosine. Int J Pharm, 2008;355:81-6.
13. Darwis Y, Kellaway IW. Nebulisation of rehydrated freeze-dried beclomethasone diproprionate liposomes. Int J Pharm, 2001;215:113-21. (Pubitemid 32206609)
14. Davies NM, Feddah MR. A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm, 2003;14:175-87. (Pubitemid 36369601)
15. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. Large porous particles for pulmonary drug delivery. Science, 1997;276:1868-71. (Pubitemid 27443665)
16. El-Baseir MM, Kellaway IW. Poly(L-lactic acid) microspheres for pulmonary drug delivery: Release kinetics and aerosolisation studies. Int J Pharm, 1998;175:135-45.
17. European Pharmacopoeia, 2010. Preparation for inhalation: Aerodynamic assessment of fine particles. 7th ed. Strasbourg, France: EDQM - Council of Europe.
18. Finlay WH, Wong JP. Regional lung deposition of nebulized liposomeencapsulated ciprofloxacin. Int J Pharm, 1998;167:121-7. (Pubitemid 28341513)
19. Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution. USA Patent No. 5250236, USA, 1993.
20. Groneberg DA, Witt C, Wagner U, Chung KF, Fisher A. Fundamentals of pulmonary drug delivery. Respir Med, 2003;97:382-7. (Pubitemid 36410606)
21. Hong Y, Hu FQ, Yuan H. Effect of PEG 2000 on drug delivery characterization from solid lipid nanoparticles. Pharmazie, 2006;61:312-15.
22. Huang W-H, Yang Z-J, Wu H, Wong Y-F, Zhao Z-Z, Liu L. Development of liposomal salbutamol sulphate dry powder inhaler formulation. Biol Pharm Bull, 2010;33:512-17.
23. Jaspart S, Bertholet P, Piel G, Dogné JM, Delattre L, Evrard B. Solid lipid microparticles as a sustained release system for pulmonary drug delivery. Eur J Pharm Biopharm, 2007;65:47-56. (Pubitemid 44827691)
24. Jaspart S, Piel G, Delattre L, Evrard B. Solid lipid microparticles: Formulation, preparation, characterisation, drug release and applications. Expert Opin Drug Deliv, 2005;2:75-87. (Pubitemid 40123884)
25. Karathanasis E, Ayyagari AL, Bhavane R, Bellamkonda RV, Annapraganda AV. Preparation of in vivo cleavable agglomerated liposomes suitable for modulated pulmonary drug delivery. J Control Release, 2005;103:159-75. (Pubitemid 40248570)
26. Kelly HW, Murphy S. Beta-adrenergic agonists for acute, severe asthma. Ann Pharmacother, 1992;26:81-91.
27. Kips JC, Pauwels RA. Long-acting inhaled β2-agonist therapy in asthma. Am J Respir Crit Care Med, 2001;164:923-32. (Pubitemid 32971634)
28. Learoyd TP, Burrows JL, French E, Seville PC. Sustained delivery of salbutamol and beclometasone from spray-dried double emulsions. J Microencapsul, 2010;27:162-70.
29. Malo JL, Cartier A, Merland N, Ghezzo H, Burek A, Morris J, Jennings BH. Four-times-a-day dosing frequency is better than twice-a-day regimen in subjects requiring a high-dose inhaled steroid, budesonide to control moderate to severe asthma. Am Rev Respir Dis, 1989;140:624-8. (Pubitemid 19234304)
30. Mezzena M, Scalia S, Young PM, Traini D. Solid lipid budesonide microparticles for controlled release inhalation therapy. AAPS J, 2009;11:771-8.
31. Müller RH, Maaßen H, Weyhers F, Specht F, Lucks JS. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm, 1996;138:85-94. (Pubitemid 26241925)
32. Müller RH, Radtke M, Wissing SA. Solid Lipid Nanoparticles (SLN) and Nanostructure Lipid Carrier (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev, 2002;54:S131-55. (Pubitemid 35379959)
33. Myers MA, Thomas DA, Straub L, Soucy W, Niven RW, Kaltenbach M, Hood CI, Schreier H, Gonzalez-Rothi RJ. Pulmonary effects of chronic exposure to liposome aerosols in mice. Exp Lung Res, 1993;19:1-19. (Pubitemid 23042785)
34. Nassimi M, Schleh C, Lauenstein HD, Hussein R, Hoymann HG, Koch W, Pohlmann G, Krug N, Sewald K, Rittinghausen S, et al. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur J Pharm Biopharm, 2010;75:107-16.
35. Pritchard JN. The influence of lung deposition on clinical response. J Aerosol Med, 2001;14:S19-26. (Pubitemid 32172850)
36. Rytting E, Bur M, Cartier R, Bouyssou T, Wang X, Krüger Lehr C-M, Kissel T. In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles. J Control Release, 2010;141:101-7.
37. Salama RO, Traini D, Chan HK, Young PM. Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation. 2: Evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharm Biopharm, 2008;70:145-52.
38. Salama RO, Traini D, Chan HK, Young PM. Recent advances in controlled release pulmonary therapy. Curr Drug Deliv, 2009a;6:404-14.
39. Salama RO, Traini D, Chan H-K, Sung A, Ammit AJ, Young PM. Preparation and evaluation of controlled release microparticles for respiratory protein therapy. J Pharm Sci, 2009b;98:2709-17.
40. Sanna V, Kirschvink N, Gustin P, Gavini E, Roland I, Delattre L, Evrard B. Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration. AAPS PharmSciTech, 2003;5:e27.
41. Scalia S, Mezzena M. Incorporation in lipid microparticles of the UVA filter, butyl methoxydibenzoylmethane combined with the UVB filter, octocrylene: Effect on photostability. AAPS PharmSciTech, 2009;10:384-90.
42. Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev, 2006;58:996-1008. (Pubitemid 44709266)
43. Sebti T, Amighi K. Preparation and in vivo evaluation of lipidic carriers and filers for inhalation. Eur J Pharm Biopharm, 2006;63:51-8.
44. Traini D, Young P. Delivery of antibiotics to the respiratory tract: An update. Expert Opin Drug Deliv, 2009;6:897-905.
45. Yu J, Chien YW. Pulmonary drug delivery:physiologic and mechanistic aspects. Crit Rev Ther Drug Carrier Syst, 1997;14:395-453. (Pubitemid 28036074)
46. Zeng XM, Martin GP, Marriott C. The controlled delivery of drugs to the lung. Int J Pharm, 1995;124:149-64.